RhumbLine Advisers’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.18M | Buy |
476,935
+114,880
| +32% | +$870K | ﹤0.01% | 1555 |
|
|
2026
Q1 | $2.78M | Buy |
362,055
+34,453
| +11% | +$236K | ﹤0.01% | 1686 |
|
|
2025
Q4 | $649K | Buy |
327,602
+12,979
| +4% | +$29.4K | ﹤0.01% | 2500 |
|
|
2025
Q3 | $774K | Sell |
314,623
-19,934
| -6% | -$51.3K | ﹤0.01% | 2402 |
|
|
2025
Q2 | $883K | Buy |
334,557
+115,197
| +53% | +$310K | ﹤0.01% | 2310 |
|
|
2025
Q1 | $660K | Buy |
219,360
+11,573
| +6% | +$35.1K | ﹤0.01% | 2385 |
|
|
2024
Q4 | $532K | Buy |
207,787
+299
| +0.1% | +$1.25K | ﹤0.01% | 2644 |
|
|
2024
Q3 | $772K | Sell |
207,488
-4,189
| -2% | -$19.4K | ﹤0.01% | 2405 |
|
|
2024
Q2 | $1.34M | Buy |
211,677
+24,802
| +13% | +$164K | ﹤0.01% | 2087 |
|
|
2024
Q1 | $1M | Buy |
186,875
+8,035
| +4% | +$36.4K | ﹤0.01% | 2245 |
|
|
2023
Q4 | $898K | Buy |
178,840
+37,045
| +26% | +$116K | ﹤0.01% | 2317 |
|
|
2023
Q3 | $240K | Sell |
141,795
-5,350
| -4% | -$10.7K | ﹤0.01% | 3056 |
|
|
2023
Q2 | $409K | Buy |
147,145
+35,371
| +32% | +$100K | ﹤0.01% | 2820 |
|
|
2023
Q1 | $203K | Sell |
111,774
-830
| -0.7% | -$2.58K | ﹤0.01% | 2738 |
|
|
2022
Q4 | $571K | Buy |
112,604
+3,077
| +3% | +$16.9K | ﹤0.01% | 2401 |
|
|
2022
Q3 | $544K | Buy |
109,527
+8,495
| +8% | +$38.7K | ﹤0.01% | 2461 |
|
|
2022
Q2 | $376K | Buy |
101,032
+12,909
| +15% | +$51.9K | ﹤0.01% | 2634 |
|
|
2022
Q1 | $494K | Sell |
88,123
-2,155
| -2% | -$13.2K | ﹤0.01% | 2432 |
|
|
2021
Q4 | $549K | Sell |
90,278
-2,130
| -2% | -$16K | ﹤0.01% | 2467 |
|
|
2021
Q3 | $900K | Buy |
92,408
+3,268
| +4% | +$36K | ﹤0.01% | 2272 |
|
|
2021
Q2 | $1.27M | Buy |
89,140
+51,249
| +135% | +$847K | ﹤0.01% | 2140 |
|
|
2021
Q1 | $900K | Sell |
37,891
-2,437
| -6% | -$63.2K | ﹤0.01% | 2229 |
|
|
2020
Q4 | $538K | Buy |
40,328
+3,170
| +9% | +$30.5K | ﹤0.01% | 2411 |
|
|
2020
Q3 | $258K | Buy |
37,158
+259
| +0.7% | +$2.58K | ﹤0.01% | 2583 |
|
|
2020
Q2 | $453K | Buy |
+36,899
| New | +$208K | ﹤0.01% | 2396 |
|
|
2019
Q2 | – | Sell |
-38,052
| Closed | -$60K | – | 2987 |
|
|
2019
Q1 | $60K | Sell |
38,052
-190
| -0.5% | -$239 | ﹤0.01% | 2908 |
|
|
2018
Q4 | $44K | Buy |
38,242
+9,570
| +33% | +$21.9K | ﹤0.01% | 2951 |
|
|
2018
Q3 | $106K | Buy |
28,672
+150
| +0.5% | +$474 | ﹤0.01% | 2860 |
|
|
2018
Q2 | $87K | Buy |
28,522
+44
| +0.2% | +$163 | ﹤0.01% | 2884 |
|
|
2018
Q1 | $111K | Sell |
28,478
-1,040
| -4% | -$4.56K | ﹤0.01% | 2729 |
|
|
2017
Q4 | $133K | Sell |
29,518
-5,491
| -16% | -$26K | ﹤0.01% | 2731 |
|
|
2017
Q3 | $192K | Buy |
35,009
+220
| +0.6% | +$1.36K | ﹤0.01% | 2751 |
|
|
2017
Q2 | $264K | Buy |
34,789
+20,646
| +146% | +$89.2K | ﹤0.01% | 2623 |
|
|
2017
Q1 | $50K | Sell |
14,143
-2,459
| -15% | -$12.2K | ﹤0.01% | 2825 |
|
|
2016
Q4 | $95K | Buy |
16,602
+737
| +5% | +$4.92K | ﹤0.01% | 2797 |
|
|
2016
Q3 | $123K | Buy |
15,865
+400
| +3% | +$2.99K | ﹤0.01% | 2786 |
|
|
2016
Q2 | $96K | Buy |
+15,465
| New | +$120K | ﹤0.01% | 2918 |
|
Other funds holding IBRX
RhumbLine Advisers's IBRX Position: Q2 2026 in Review
RhumbLine Advisers increased its ImmunityBio (IBRX) stake by 32% in Q2 2026, buying an estimated $870K and bringing the position to 476,935 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1555.
RhumbLine Advisers first reported a position in IBRX in Q2 2016 and has held it in 37 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- RhumbLine Advisers held 476,935 shares of ImmunityBio worth $4.18M as of Q2 2026.
- RhumbLine Advisers bought 114,880 ImmunityBio shares in Q2 2026, an estimated $870K.
- ImmunityBio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1555 holding.
- RhumbLine Advisers first reported a position in ImmunityBio in Q2 2016 and has held it in 37 quarters since.
- 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.